When choosing between ranibizumab and aflibercept for treating neovascular age-related macular degeneration, neither drug bests the other in terms of visual acuity outcomes and treatment frequency at 3 years, according to data from the Fight Retinal Blindness! Registry.
New drug applications approved by US FDA as of 01 - 15 March 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Damage to small blood vessels of the eye appears to be a significant marker for an increased risk of stroke in patients with diabetes, suggesting that the microvascular pathology inherent to diabetic retinopathy may have greater cardiovascular implications, according to a study presented at the American Stroke Association’s (ASA) International Stroke Conference (ISC) 2020 in Los Angeles, US.
Deep learning models accurately identify eyes with glaucomatous visual field damage (GVFD) and predict functional loss severity from spectral domain optical coherence tomography (SD OCT) images, reports a study.
Treatment with teprotumumab in patients with active thyroid eye disease confers beneficial effects on proptosis, Clinical Activity Score, diplopia and quality of life, without increasing the incidence of serious adverse events, according to the results of a phase III trial.
Use of biologic agents in eyes with refractory, active, noninfectious intermediate uveitis, posterior uveitis or panuveitis (NIPPU) is associated with satisfactory disease control, reduced use of systemic immunosuppression, stable visual acuity and a 23.7-percent risk of disease relapse, reveals a study.
The baseline inferior subfield retinal thickness may predict the frequency of treatment for diabetic macular oedema (DME) during the first year in eyes administered pro re nata (PRN) intravitreal ranibizumab (IVR) injections, a new study shows.